Washington D.C. – Pfizer and BioNTech announced Monday that their coronavirus vaccine is more than 90 percent effective in preventing COVID-19. The effectiveness increases among those patients without any prior infections. The pandemic has claimed over 1.2 million lives worldwide. With that, this announcement is a breath of fresh air for drug makers striving to invent a safe and effective COVID-19 vaccine.
Scientists are now hoping that in practice, the vaccine is at least 75 percent effective. White House coronavirus advisor Dr. Anthony Fauci claims that a 50-60 percent effective vaccine is acceptable. As a comparison, the seasonal flu vaccine has a 40-60% effectiveness rate.
Pfizer’s vaccine efficacy rate is based on clinical studies from the first interim efficacy analysis by the Data Monitoring Committee. Experts foresee that the vaccine could be available in limited use as early as December 2020. It’s expected that in the third quarter of 2021 the vaccine will be widely available.
According to experts, the Pfizer vaccine is a medical breakthrough. It’s the most significant medical advancement in the last hundred years. Obviously, this will have a great deal of impact on global health and the economy.
Will Pfizer face distribution challenges while adhering to the Food and Drug Administration (FDA) guidelines?
Thumbnail Credit: Reuters (image may be subject to copyright)